Voyager Therapeutics (NASDAQ:VYGR) Share Price Passes Below 50 Day Moving Average – Here’s What Happened

Voyager Therapeutics, Inc. (NASDAQ:VYGR)’s share price crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $4.62 and traded as low as $3.85. Voyager Therapeutics shares last traded at $3.91, with a volume of 214,629 shares trading hands.

Wall Street Analyst Weigh In

A number of research firms recently commented on VYGR. Wells Fargo & Company set a $10.00 target price on shares of Voyager Therapeutics and gave the stock an “overweight” rating in a research note on Wednesday, March 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Canaccord Genuity Group reduced their target price on shares of Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, March 13th. Finally, Wedbush reaffirmed an “outperform” rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $14.86.

Voyager Therapeutics Price Performance

The company’s 50 day simple moving average is $4.62 and its 200 day simple moving average is $5.71. The company has a market capitalization of $215.86 million, a PE ratio of 5.51 and a beta of 0.99.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). The company had revenue of $4.39 million during the quarter, compared to analyst estimates of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter last year, the business earned $1.25 EPS. On average, equities analysts forecast that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in VYGR. Cubist Systematic Strategies LLC bought a new position in shares of Voyager Therapeutics during the 4th quarter valued at about $29,000. Tower Research Capital LLC TRC boosted its stake in shares of Voyager Therapeutics by 133.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after acquiring an additional 3,077 shares in the last quarter. Picton Mahoney Asset Management grew its holdings in shares of Voyager Therapeutics by 71.1% in the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock worth $33,000 after acquiring an additional 2,444 shares during the last quarter. Oxford Asset Management LLP acquired a new stake in shares of Voyager Therapeutics during the fourth quarter worth $60,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Voyager Therapeutics during the third quarter valued at $74,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.